IMA
ImageneBio IncNASDAQHealthcare$4.97-1.58%ClosedMarket Cap: $55.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.42
P/S
0.00
EV/EBITDA
-0.61
DCF Value
$4.98
FCF Yield
-86.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-34.0%
ROA
-28.2%
ROIC
-37.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-6.9M | $-0.62 |
| FY 2025 | $800.0K | $-45.3M | $-10.76 |
| Q3 2025 | $0.00 | $-24.8M | $-3.01 |
| Q2 2025 | $0.00 | $-2.8M | $-0.06 |
Analyst Ratings
View AllWedbushNeutral
2025-07-25Trading Activity
Insider Trades
View AllYarema Kristindirector, officer: Chief Executive Officer
SellWed Mar 18
Yarema Kristindirector, officer: Chief Executive Officer
SellWed Mar 18
Porter-Brown Benjamin
SellFri Feb 20
Butler Erinofficer: Principal Accounting Officer
SellFri Jan 02
SLATTERY JOSEPH Pdirector
BuyMon Dec 29
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.45
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis